Portfolio of Cancer Immunotherapy Stocks
Here are 23 cancer immunotherapy stocks.
|23 Cancer Immunotherapy Stocks|
Stock Returns & Price Chart
Recent Prices &
|Five Prime Therapeutics||FPRX|
|Price data from Quandl as of most recent close.|
The 14 stocks included in the portfolio
computations are: AMGN, AZN, BMY, CELG, CLDX, CGEN, CRIS, GILD, INCY, MRK, NKTR, NVS, PFE and ZIOP. The current value of the portfolio assumes that $714.29 was invested (total of $10,000) in each stock at its closing monthly price for the current date in 2009. All prices are adjusted for splits and dividends. The 9 stocks excluded from the portfolio computations because of insufficient price data are: BGNE, BLCM, BLUE, CLLS, CYAD, CLVS, CTMX, FPRX and NK.
To inspect the performance of the Cancer Immunotherapy Stocks portfolio, see the chart of portfolio below. Portfolio values are computed using monthly closes for stocks from Quandl.
The current value of a $10,000 investment is $61,975. The percent return is 519.75%. The annualized return is 20.01%.